MedKoo Cat#: 573114 | Name: Memantine free base
New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Memantine is an amantadine derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent and has may be used to treat moderate to severe Alzheimer's disease. It acts on the glutamatergic system by blocking NMDA receptors.

Chemical Structure

Memantine free base
Memantine free base
CAS#19982-08-2 (free base)

Theoretical Analysis

MedKoo Cat#: 573114

Name: Memantine free base

CAS#: 19982-08-2 (free base)

Chemical Formula: C12H21N

Exact Mass: 179.1674

Molecular Weight: 179.31

Elemental Analysis: C, 80.38; H, 11.81; N, 7.81

Price and Availability

Size Price Availability Quantity
1g USD 150.00 Ready to ship
2g USD 250.00 Ready to ship
5g USD 450.00 Ready to ship
10g USD 750.00 Ready to ship
25g USD 1,250.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Memantine; D 145; D-145; NSC 102290; SUN Y7017; Ebixa; Ebixza; Akatinol; Axura;
IUPAC/Chemical Name
1-Amino-3,5-dimethyladamantane
InChi Key
BUGYDGFZZOZRHP-UHFFFAOYSA-N
InChi Code
1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
SMILES Code
C1[C@@]2(CC3(CC(C2)C[C@@]1(C3)C)N)C
Appearance
Colorless liquid
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Certificate of Analysis
Safety Data Sheet (SDS)
Biological target:
Memantine is an amantadine derivative that has some dopaminergic effects.
In vitro activity:
Memantine activated AMPK A1 and AMPK A2 genes at mRNA level significantly (p=0.039 and p=0.0105) (Figure 2a, 2b(Fig. 2)). Memantine treatment decreased HIF1A, B-catenin and PKM protein expression levels (Figure 2c, 2d(Fig. 2)). All of these targets are involved in cancer cell metabolism related changes in oncogenic transformation of the cells. Reference: EXCLI J. 2021; 20: 223–231. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192876/
In vivo activity:
To determine whether memantine improves spatial learning and memory, Morris water maze (MWM) test was conducted in control and memantine treated APP/PS1 mice. The trace records (Fig. 1A) showed that the swimming trajectory of APP/PS1 mice in the target quadrant was smaller than those of WT mice and memantine treated APP/PS1 mice. There was no significant difference in swimming speed among these three groups (Fig. 1B). And the escape latency in different test days of training was significant for these different treatment groups (Fig. 1C). The APP/PS1 mice took more time to find the target quadrant and decreased the number of platform crossings (Fig. 1D, E). Furthermore, both parameters could be significantly improved after memantine treatment in APP/PS1 mice (Fig. 1D, E, n = 8, one-way ANOVNs, P < 0.05). Taken together, these data suggested that memantine was effective in improving the spatial memory in APP/PS1 mice. Reference: BMC Neurosci. 2021 Jun 14;22(1):41. https://bmcneurosci.biomedcentral.com/articles/10.1186/s12868-021-00647-y

Preparing Stock Solutions

The following data is based on the product molecular weight 179.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Albayrak G, Demirtas Korkmaz F. Memantine shifts cancer cell metabolism via AMPK1/2 mediated energetic switch in A549 lung cancer cells. EXCLI J. 2021 Feb 4;20:223-231. doi: 10.17179/excli2020-2890. PMID: 34121969; PMCID: PMC8192876. 2. Lv X, Li Q, Mao S, Qin L, Dong P. The protective effects of memantine against inflammation and impairment of endothelial tube formation induced by oxygen-glucose deprivation/reperfusion. Aging (Albany NY). 2020 Nov 7;12(21):21469-21480. doi: 10.18632/aging.103914. Epub 2020 Nov 7. PMID: 33174867; PMCID: PMC7695423. 3. Li P, Xu J, Gu H, Peng H, Yin Y, Zhuang J. Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal-CA1 projection. BMC Neurosci. 2021 Jun 14;22(1):41. doi: 10.1186/s12868-021-00647-y. PMID: 34120588. 4. Matsumura M, Sato K, Kubota T, Kishimoto Y. Spatial and latent memory data in PS2Tg2576 alzheimer's disease mouse model after memantine treatment. Data Brief. 2021 May 12;36:107131. doi: 10.1016/j.dib.2021.107131. PMID: 34095380; PMCID: PMC8166749.
In vitro protocol:
1. Albayrak G, Demirtas Korkmaz F. Memantine shifts cancer cell metabolism via AMPK1/2 mediated energetic switch in A549 lung cancer cells. EXCLI J. 2021 Feb 4;20:223-231. doi: 10.17179/excli2020-2890. PMID: 34121969; PMCID: PMC8192876. 2. Lv X, Li Q, Mao S, Qin L, Dong P. The protective effects of memantine against inflammation and impairment of endothelial tube formation induced by oxygen-glucose deprivation/reperfusion. Aging (Albany NY). 2020 Nov 7;12(21):21469-21480. doi: 10.18632/aging.103914. Epub 2020 Nov 7. PMID: 33174867; PMCID: PMC7695423.
In vivo protocol:
1. Li P, Xu J, Gu H, Peng H, Yin Y, Zhuang J. Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal-CA1 projection. BMC Neurosci. 2021 Jun 14;22(1):41. doi: 10.1186/s12868-021-00647-y. PMID: 34120588. 2. Matsumura M, Sato K, Kubota T, Kishimoto Y. Spatial and latent memory data in PS2Tg2576 alzheimer's disease mouse model after memantine treatment. Data Brief. 2021 May 12;36:107131. doi: 10.1016/j.dib.2021.107131. PMID: 34095380; PMCID: PMC8166749.
1: Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, Chou KR. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One. 2017 Aug 21;12(8):e0183586. doi: 10.1371/journal.pone.0183586. eCollection 2017. PubMed PMID: 28827830; PubMed Central PMCID: PMC5565113. 2: Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. eCollection 2016. Review. PubMed PMID: 27757016; PubMed Central PMCID: PMC5055113. 3: Greig SL. Memantine ER/Donepezil: A Review in Alzheimer's Disease. CNS Drugs. 2015 Nov;29(11):963-70. doi: 10.1007/s40263-015-0287-2. Review. PubMed PMID: 26519339. 4: Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 2015. Review. PubMed PMID: 25860130; PubMed Central PMCID: PMC4393306.